Alumis (NASDAQ:ALMS – Get Free Report) is projected to release its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.90 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Alumis (NASDAQ:ALMS – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. The firm had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. On average, analysts expect Alumis to post ($2.95) EPS for the current fiscal year and ($2.84) EPS for the next fiscal year.
Alumis Stock Performance
Shares of Alumis stock opened at $6.55 on Thursday. Alumis has a 52-week low of $4.40 and a 52-week high of $31.35. The company’s 50 day moving average price is $8.82 and its 200-day moving average price is $21.14.
Insider Buying and Selling at Alumis
In related news, Director Srinivas Akkaraju sold 96,131 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $10.55, for a total value of $1,014,182.05. Following the completion of the transaction, the director directly owned 2,025,493 shares in the company, valued at $21,368,951.15. This trade represents a 4.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 99,754 shares of company stock valued at $1,037,804. 33.70% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of equities research analysts recently commented on ALMS shares. Morgan Stanley lowered their price target on shares of Alumis from $39.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, September 2nd. Citigroup restated an “overweight” rating on shares of Alumis in a research report on Tuesday, September 1st. HC Wainwright restated a “buy” rating on shares of Alumis in a research report on Monday, October 5th. Robert W. Baird set a $27.00 price objective on shares of Alumis in a research note on Tuesday, September 1st. Finally, Weiss Ratings lowered shares of Alumis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alumis has an average rating of “Moderate Buy” and an average price target of $33.27.
Read Our Latest Research Report on ALMS
About Alumis
Alumis (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research is centered on selective modulation of the immune system, with the goal of providing effective, convenient treatments that may address conditions inadequately served by existing therapies.
Its lead product candidate, ESK-001, is an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor designed to selectively regulate signaling pathways involved in inflammatory and autoimmune diseases.
Read More
- Five stocks we like better than Alumis
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
